Phone (336) 292-1510
Fax (336) 292-0679

Receive our eNewsletter

  Home  
  Our Team  
  Patient Info  
  Services  

News for Healthier Living

Comprehensive Molecular Profiling of Renal Medullary Carcinoma Identifies TROP2 as a Promising Therapeutic Target

Researchers at The University of Texas MD Anderson Cancer Center, in collaboration with BostonGene, conducted the largest and most comprehensive molecular analysis of renal medullary carcinoma (RMC), a rare and aggressive form of kidney cancer, leading to the identification of TROP2 as a promising therapeutic target.

October 30, 2025


November 5 2025

November 4 2025

November 3 2025

November 2 2025

November 1 2025

October 31 2025

October 30 2025

October 29 2025

October 28 2025

October 27 2025

October 26 2025

October 25 2025

October 24 2025

October 23 2025